Climate change, wildfire aftermath, and lack of a reliable vaccine raise concerns that dengue may become endemic in parts of the U.S. as mosquito season intensifies.
Older Americans are embracing vaccines—backed by new research confirming enhanced safety, disease prevention, and even a potential link to reduced dementia risk.
FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.